The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Duborimycin     (7S,9R)-7-[(2S,4S,5S,6S)-4- amino-5-hydroxy...

Synonyms: Daunomycinol, Daunorubicinol, SureCN1136412, CHEBI:31059, KST-1A3492, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Daunomycinol


High impact information on Daunomycinol


Chemical compound and disease context of Daunomycinol


Biological context of Daunomycinol


Anatomical context of Daunomycinol


Associations of Daunomycinol with other chemical compounds


Gene context of Daunomycinol


Analytical, diagnostic and therapeutic context of Daunomycinol


  1. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. List, A.F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M., Dalton, W. J. Clin. Oncol. (1993) [Pubmed]
  2. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. Kokenberg, E., Sonneveld, P., Sizoo, W., Hagenbeek, A., Löwenberg, B. J. Clin. Oncol. (1988) [Pubmed]
  3. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia. Pea, F., Russo, D., Michieli, M., Damiani, D., Fanin, R., Michelutti, A., Michelutti, T., Piccolrovazzi, S., Baccarani, M., Furlanut, M. Clinical pharmacokinetics. (2003) [Pubmed]
  4. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat. Cusack, B.J., Young, S.P., Vestal, R.E., Olson, R.D. Cancer Chemother. Pharmacol. (1997) [Pubmed]
  5. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Zucchetti, M., Boiardi, A., Silvani, A., Parisi, I., Piccolrovazzi, S., D'Incalci, M. Cancer Chemother. Pharmacol. (1999) [Pubmed]
  6. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Gonzalez, B., Akman, S., Doroshow, J., Rivera, H., Kaplan, W.D., Forrest, G.L. Cancer Res. (1995) [Pubmed]
  7. In vivo and in vitro bioconversion of epsilon-rhodomycinone glycoside to doxorubicin: functions of DauP, DauK, and DoxA. Dickens, M.L., Priestley, N.D., Strohl, W.R. J. Bacteriol. (1997) [Pubmed]
  8. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Guaglianone, P., Chan, K., DelaFlor-Weiss, E., Hanisch, R., Jeffers, S., Sharma, D., Muggia, F. Investigational new drugs. (1994) [Pubmed]
  9. Microbial metabolism of anthracycline antibiotics daunomycin and adriamycin. Marshall, V.P., McGovren, J.P., Richard, F.A., Richard, R.E., Wiley, P.F. J. Antibiot. (1978) [Pubmed]
  10. Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Cusack, B.J., Mushlin, P.S., Voulelis, L.D., Li, X., Boucek, R.J., Olson, R.D. Toxicol. Appl. Pharmacol. (1993) [Pubmed]
  11. Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Olson, R.D., Li, X., Palade, P., Shadle, S.E., Mushlin, P.S., Gambliel, H.A., Fill, M., Boucek, R.J., Cusack, B.J. Toxicol. Appl. Pharmacol. (2000) [Pubmed]
  12. Distribution of daunorubicin intravenously injected or intravenously infused as free drug and as a complex with DNA in rabbits. Hulhoven, R., Harvengt, C. Pharmacology (1982) [Pubmed]
  13. Nuclear binding as a determinant of tissue distribution of adriamycin, daunomycin, adriamycinol, daunorubicinol and actinomycin D. Terasaki, T., Iga, T., Sugiyama, Y., Sawada, Y., Hanano, M. J. Pharmacobio-dyn. (1984) [Pubmed]
  14. Metabolism of the anthracycline antibiotic daunorubicin to daunorubicinol and deoxydaunorubicinol aglycone in hepatocytes isolated from the rat and the rabbit. Gewirtz, D.A., Yanovich, S. Biochem. Pharmacol. (1986) [Pubmed]
  15. Interactions between cyclophosphamide and doxorubicin metabolism in rats. II. Effect of cyclophosphamide on the aldoketoreductase system. Dodion, P., Akman, S.R., Tamburini, J.M., Riggs, C.E., Colvin, O.M., Bachur, N.R. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
  16. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells. Tidefelt, U., Prenkert, M., Paul, C. Cancer Chemother. Pharmacol. (1996) [Pubmed]
  17. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Schott, B., Robert, J. Biochem. Pharmacol. (1989) [Pubmed]
  18. Quantitative determination of low levels of daunomycin and daunomycinol in plasma by high-performance liquid chromatography. Hulhoven, R., Desager, J.P. J. Chromatogr. (1976) [Pubmed]
  19. Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. Application to L1210 cells. Baurain, R., Zenebergh, A., Trouet, A. J. Chromatogr. (1978) [Pubmed]
  20. Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients. Eksborg, S., Ehrsson, H., Andersson, B., Beran, M. J. Chromatogr. (1978) [Pubmed]
  21. Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance. Le Bot, M.A., Kernaleguen, D., Robert, J., Berlion, M., Riché, C. Cancer Chemother. Pharmacol. (1994) [Pubmed]
  22. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. Akman, S.A., Forrest, G., Chu, F.F., Esworthy, R.S., Doroshow, J.H. Cancer Res. (1990) [Pubmed]
  23. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Callies, S., de Alwis, D.P., Mehta, A., Burgess, M., Aarons, L. Cancer Chemother. Pharmacol. (2004) [Pubmed]
  24. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. Tidefelt, U., Liliemark, J., Gruber, A., Liliemark, E., Sundman-Engberg, B., Juliusson, G., Stenke, L., Elmhorn-Rosenborg, A., Möllgård, L., Lehman, S., Xu, D., Covelli, A., Gustavsson, B., Paul, C. J. Clin. Oncol. (2000) [Pubmed]
  25. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. Pea, F., Russo, D., Michieli, M., Baraldo, M., Ermacora, A., Damiani, D., Baccarani, M., Furlanut, M. Cancer Chemother. Pharmacol. (2000) [Pubmed]
  26. A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography. Bolanowska, W., Gessner, T., Preisler, H. Cancer Chemother. Pharmacol. (1983) [Pubmed]
  27. Daunomycin and daunomycinol plasma levels measured by HPLC after perfusions of daunomycin and daunomycin-DNA complex in rabbits: a preliminary report. Hulhoven, R., Desager, J.P., Sokal, G., Harvengt, C. Archives internationales de pharmacodynamie et de thérapie. (1977) [Pubmed]
WikiGenes - Universities